INVESTABOT
Equity Research
XNAS · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Gilead Sciences (GILD) had 2 Form 144 pre-sale notices filed on 2026-09-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Gilead Sciences (GILD) had 1 Form 144 pre-sale notice filed on 2026-08-26. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Gilead Sciences (GILD) had 1 Form 144 pre-sale notice filed on 2026-08-20. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Gilead Sciences (GILD) had 2 Form 144 pre-sale notices filed on 2026-08-17. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Gilead Sciences (GILD) had 1 Form 144 pre-sale notice filed on 2026-08-03. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Gilead Sciences (GILD) had 2 Form 144 pre-sale notices filed on 2026-07-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Gilead Sciences (GILD) had 2 Form 144 pre-sale notices filed on 2026-06-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Gilead Sciences (GILD) had 1 Form 144 pre-sale notice filed on 2026-06-01. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Gilead Sciences (GILD) had 2 Form 144 pre-sale notices filed on 2026-05-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
TL;DR: Gilead Sciences reported Q1 2026 EPS of $1.61, up 54.8% from $1.04 a year ago, on total revenues of $7.0 billion. The company immediately raised its full-year revenue guidance, signaling management's confidence…
Gilead Sciences (GILD) had 3 Form 144 pre-sale notices filed between 2026-04-15 and 2026-04-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed…
Gilead Sciences Inc (GILD) had 3 Form 144 pre-sale notices filed between 2026-04-15 and 2026-04-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed…
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 7 unique sellers · 8 accumulating - 6 trimming - 0 unchanged
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 22, 2026 | Burkhart Erin | SVP, Controllership | OPTION_EXERCISE | -2,223 | — | — |
| September 22, 2026 | Burkhart Erin | SVP, Controllership | TAX_WITHHOLD | -768 | $153 | ~$0.1M |
| September 22, 2026 | Burkhart Erin | SVP, Controllership | OPTION_EXERCISE | 2,223 | — | — |
| September 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | -600 | $145 | ~$87K |
| September 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | -800 | $144 | ~$0.1M |
| September 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | SELL | -1,600 | $144 | ~$0.2M |
| September 15, 2026 | Dickinson Andrew D | Chief Financial Officer | SELL | -3,000 | $145 | ~$0.4M |
| September 10, 2026 | O'Day Daniel Patrick | Chairman & CEO | OPTION_EXERCISE | -8,780 | — | — |
| September 10, 2026 | O'Day Daniel Patrick | Chairman & CEO | TAX_WITHHOLD | -4,230 | $145 | ~$0.6M |
| September 10, 2026 | O'Day Daniel Patrick | Chairman & CEO | OPTION_EXERCISE | 8,780 | — | — |
| September 10, 2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | OPTION_EXERCISE | -590 | — | — |
| September 10, 2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | TAX_WITHHOLD | -285 | $145 | ~$41K |
| September 10, 2026 | Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | OPTION_EXERCISE | 590 | — | — |
| September 10, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | OPTION_EXERCISE | -2,797 | — | — |
| September 10, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | TAX_WITHHOLD | -1,347 | $145 | ~$0.2M |
| September 10, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | OPTION_EXERCISE | 2,797 | — | — |
| September 10, 2026 | Berger Dietmar | Chief Medical Officer | OPTION_EXERCISE | -533 | — | — |
| September 10, 2026 | Berger Dietmar | Chief Medical Officer | TAX_WITHHOLD | -263 | $145 | ~$38K |
| September 10, 2026 | Berger Dietmar | Chief Medical Officer | OPTION_EXERCISE | 533 | — | — |
| September 10, 2026 | Dickinson Andrew D | Chief Financial Officer | OPTION_EXERCISE | -2,797 | — | — |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| September 15, 2026 | Johanna Mercier | — | 3,000 | SEC |
| September 15, 2026 | Andrew Dickinson | — | 3,000 | SEC |
| August 26, 2026 | Anthony Welters | — | 18,000 | SEC |
| August 20, 2026 | Jeffrey Bluestone | — | 5,000 | SEC |
| August 17, 2026 | Andrew Dickinson | — | 3,000 | SEC |
| August 17, 2026 | Johanna Mercier | — | 28,000 | SEC |
| August 3, 2026 | Daniel O'Day | — | 55,000 | SEC |
| July 15, 2026 | Andrew Dickinson | — | 3,000 | SEC |
| July 15, 2026 | Johanna Mercier | — | 3,000 | SEC |
| June 15, 2026 | Johanna Mercier | — | 3,000 | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 119,010,973 | ~$16.6B | -3.4% | May 13, 2026 |
| BlackRock | 121,844,108 | ~$15.4B | 2.4% | August 7, 2026 |
| BlackRock | 123,195,578 | ~$15.1B | — | February 12, 2026 |
| Vanguard Group | 121,097,336 | ~$14.9B | — | January 29, 2026 |
| Fidelity (FMR) | 71,906,290 | ~$10.0B | 9.7% | May 15, 2026 |
| Fidelity (FMR) | 66,870,816 | ~$8.4B | -7.0% | August 13, 2026 |
| State Street | 59,858,585 | ~$8.3B | -0.6% | May 15, 2026 |
| BlackRock | 120,632,023 | ~$8.3B | — | August 13, 2024 |
| Fidelity (FMR) | 65,579,490 | ~$8.0B | — | February 17, 2026 |
| State Street | 61,216,552 | ~$7.7B | 2.3% | August 7, 2026 |
| State Street | 60,240,518 | ~$7.4B | — | February 13, 2026 |
| JP Morgan Chase | 34,371,910 | ~$4.7B | 44.0% | May 13, 2026 |
| Morgan Stanley | 23,299,295 | ~$3.2B | -0.9% | May 15, 2026 |
| Morgan Stanley | 24,004,354 | ~$3.0B | 3.0% | August 13, 2026 |
| JP Morgan Chase | 23,871,863 | ~$2.9B | — | February 11, 2026 |
| Morgan Stanley | 23,512,734 | ~$2.9B | — | May 27, 2026 |
| JP Morgan Chase | 21,353,121 | ~$2.7B | -37.9% | August 12, 2026 |
| Goldman Sachs | 11,542,014 | ~$1.6B | 30.9% | May 15, 2026 |
| Goldman Sachs | 11,199,994 | ~$1.4B | -3.0% | August 14, 2026 |
| Goldman Sachs | 8,814,813 | ~$1.1B | — | March 25, 2026 |